TRGFT-201 by Orca Biosystems for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

TRGFT-201 is under clinical development by Orca Biosystems and currently in Phase III for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase III drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how TRGFT-201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TRGFT-201 overview

TRGFT-201 is under development for the treatment of myelodysplastic syndrome, acute myeloid leukemia, acute lymphoid leukemia, hematopoietic stem cell transplant, myelofibrosis, blastic plasmacytoid dendritic cell neoplasm (Natural killer cell lymphomas), chronic myelocytic leukemia. It was also under development for other unspecified indications.

Orca Biosystems overview

Orca Biosystems (Orca Bio) is a clinical-stage biotechnology company developing a pipeline of high precision allogeneic cell therapy products that are designed to safely replace patients’ diseased blood and immune system with a healthy one. The company is headquartered in Menlo Park, California, the US.

For a complete picture of TRGFT-201’s drug-specific PTSR and LoA scores, buy the report here.